December 19, 2023

San Diego, CA, December 19, 2023 – Lassen Therapeutics, a clinical stage biotech company developing first-in-class antibody therapeutics, today announced the closing of an oversubscribed Series B financing which raised $85 million. Frazier Life Sciences co-led the financing along with new investor Longitude Capital. The syndicate also included new investors BVF Partners and Catalio Capital Management as well as existing investors, Alta Partners and Longwood Capital. Concurrent with this financing, Brian Liu, M.D. from Longitude Capital and Matthew Hobson, Ph.D. from Catalio Capital Management have joined the Board of Directors.

Proceeds from this financing will support the LASN01 clinical program targeting interleukin-11 receptor (IL-11R) as a potential treatment for fibro-inflammatory diseases such as TED and IPF and advance IND-enabling activities for LASN500 targeting the interleukin-18 binding protein (IL-18BP) as a potential treatment for cancer.

FLG partner Nancy Hargreaves assisted.

Full press release is here.